Vincentage Pharma Co., Ltd
Quick facts
Phase 3 pipeline
- VCT220 Tablet · Cardiovascular
VCT220 Tablet is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: